Joseph Press serves as Executive at Raphael Pharmaceutical Inc., where they oversee executive responsibilities. Since joining the company, Joseph Press has executed 1 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Jul 26, 2022 involved receiving (via award) 280,000 shares valued at $0.
| DATE | TICKER | VALUE | TYPE | SHARES | PRICE | 10b5-1 |
|---|---|---|---|---|---|---|
| Jul 26, 2022 | RAPH | $0 | Award | 280,000 | $N/A | Discretionary |
Joseph Press currently holds 280,000 shares of Raphael Pharmaceutical Inc. (RAPH), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Joseph Press has been a net neutral trader of RAPH stock. They have purchased $0 and sold $0 worth of shares.
Joseph Press's most recent insider trade was on Jul 26, 2022, when they sold 280,000 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted